Bleeding Times in Rats Treated with Heparin, Heparin Fragments of High and Low Anticoagulant Activity and chemically Modified Heparin Fragments of Low Anticoagulant Activity

Summary

A template bleeding time study in the rat was undertaken to see if it is possible to correlate bleeding times with the molecular weight, anticoagulant activity or chemical composition of heparin or heparin-derived compounds. Heparin from porcine intestinal rnucosa (PM-heparin) and from bovine lung (BL-heparin) as well as heparin fragments from these sources were compared. Heparin fragments of low anticoagulant activity were prepared by affinity chromatography on immobilized antithrombin as well as by chemical modification. A heparin fragment of high affinity for antithrombin (HA-fragment) caused a marked and dose-dependent increase in bleeding time while the corresponding heparin fragment with low affinity for antithrombin (LA-frugment) had a marginal and non-dose dependent effect on the bleeding time. Similar results were also obtained with PM-heparin with high and low affinity for antithrombin. A high anti-FXa activity was not always correlated with a marked bleeding tendency. Provided that a fragment was devoid of activated partial thromboplastin time (APTT) activity, it was not possible to provoke a bleeding time of 20 min or longer, although the compound was administered at a dose of 1,088 U/kg (anti-FXa activity). On the other hand, & Nacetylated chemically oversulphated heparin fragment, with a very low anti-FXa activity (1 U/mg) and with an APTT activity of 34UlmtB, caused a bleeding time of 20 min or longer in 70% of the animals after injection of the same number of Aprr units, 1,088 U/kg. These data indicate that the APTT activity is a better and more sensitive indicator of the bleeding than is the anti-FXa activity.

• References

• 1 Mant MJ, Thong KL, Birtwhistle RV, O’Brien BD, Hammond GW, Grace MG. Haemorrhagic complications of heparin therapy. Lancet 1977; 1133-1135
• 2 Sié P, Fernandez F, Caranobe C, Gabaig AM, Boneu B. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulphate and pentosan polysulphate. Thromb Res 1984; 35: 231-236
• 3 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
• 4 Carter J, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 5 Doutremepuich C, Toulemonde F, Bousquet F, Bonini F. Comparison of the haemorrhagic effects of unfractionated heparin and a low molecular weight heparin fraction (CY216) in rabbits. Thromb Res 1986; 43: 691-695
• 6 Schmitz-Huebner U, Bunk H, Freise G, Reers B, Riischemeyer C, Scherer R, Schulte H, van de Loo J. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wschr 1984; 349-353
• 7 Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicenter trial on prevention of postoperative thrombosis. Br J Surg 1985; 73: 204-208
• 8 Thunberg L, Backstrom G, Grundberg H, Riesenfeld J, Lindahl U. The molecular size of the antithrombin-binding sequence in heparin. Febs Lett 1980; 117: 203-206
• 9 Horton D, Philips KD. The nitrous acid deamination of glycosides and acetates of 2-amino-2-deoxy-D-glucose. Carbohydr Res 1973; 30: 367-374
• 10 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE C. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
• 11 Inoue Y, Nagasawa K. Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol. Carbohydr Res 1976; 46: 87-95
• 12 Danishefsky I, Eiber HB, Carr JJ. Investigations on the chemistry of heparin. I. Desulfation and acetylation. Arch Biochem Biophys 1960; 90: 114-121
• 13 Ogamo A, Nagai A, Nagasawa K. Binding of heparin fractions and other polysulfated polysaccharides to plasma fibronectin: effects of molecular size and degree of sulfation of polysaccharides. Biochim Biophys Acta 1985; 841: 30-41
• 14 Nagasawa K, Inoue Y, Kamata T. Solvolytic desulfation of gly-cosaminoglycuronan sulfates with dimethyl sulfoxide containing water or methanol. Carbohydr Res 1977; 58: 47-55
• 15 Dimitriev BA, Knirel YA, Kochetkov NK. Selective cleavage of glycosidic linkages: studies with the O-specific polysaccharide from Shigella dysenteria type 3. Carbohydr Res 1975; 40: 365-372
• 16 Lloyd AG, Embery G, Fowler LJ. Studies on heparin degradation -1. Preparation of (35S) sulfamate derivatives for studies on heparin degrading enzymes of mammalian origin. Biochem Pharmacol 1971; 20: 637-648
• 17 Taylor RL, Shively JE, Conrad EH. Stoichiometric reduction of uronic acid carboxylic groups in polysaccharides in methods. In: Carbohydrate Chem VII Whistler RL, Be Miller JN. (eds). Academic Press; New York: 1976: 149-151
• 18 Casu B, Scovenna G, Cifonelli AJ, Perlin AS. Infrared spectra of glycosaminoglycans in deuterium oxide and deuteriumchloride solution: Quantitative evaluation of uronic acid and acetamidodeoxyhex-ose moieties. Carbohydr Res 1978; 63: 13-27
• 19 Casu B, Gennaro H. A conductimetric method for the determination of sulfate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr Res 1975; 39: 168-176
• 20 Dejana E, Callioni A, Quintana A, Gaetano G. Bleeding time in laboratory animals. II. A comparison of different assay conditions in rats. Thromb Res 1979; 15: 191-197
• 21 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated FX. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-541
• 22 Kakkar VV, Murray WJ G. Efficacy and safety of low-molecular weight heparin (CY216) in preventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786-791
• 23 Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. Thromb Haemostas 1988; 59: 216-220
• 24 Persson E, Nordenstrom J, Nilsson-Ehle P, Hagenfeld L. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur J Clin Invest 1985; 15: 215-220
• 25 Vitoux JF, Mathieu JF, Roncato M, Fiessinger JN, Aiach M. Heparin associated thrombocytopenia treatment with low molecular weight heparin. Thromb Haemostas 1986; 55: 37-39
• 26 Bergqvist D, Hedner U, Sjorlin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-391
• 27 Novak E, Sekhar C, Dunham N, Coleman L. A comparative study of the effect of lung and gut heparins on the platelet aggregation and protamine neutralization in man. Clin Med 1972; July 22-27
• 28 Abbot W, Warnock D, Austen G. The relationship of heparin source to the incidence of delayed haemorrhage. J Surg Res 1977; 22: 593-597
• 29 Fiser WP, Read RC, Wright FE, Vecchio TJ. A randomized study of beef and pork mucosal heparin in cardiac surgery. Ann Thorac Surg 1983; 6: 615-620
• 30 Carter C, Kelton J, Hirsh J. Comparison of the haemorrhagic effects of porcine and bovine heparin in rabbits. Thromb Res 1979; 15: 581-586
• 31 Bienkowsky MJ, Conrad EH. Structural characterization of the oligosaccharides formed by depolymerization of heparin with nitrous acid. J Biol Chem 1985; 260: 356-365
• 32 Casu B, Naggi A, Oreste P, Torri G, Pangrazzi J, Maggi A, Abbadini M, Donati M. Bleeding associated with heparin contaminants. Lancet 1987; 1: 1088